Loading…
Employees: 364
Size Shanghai Pioneer (1345.HK) is a Hong Kong Health Care company (Medical Distributors) with a market value of $300M, the 886th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$1.95 on 6 Nov 2026.
Performance Over six months the shares fell 17.7%, against -5.6% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 5.8% over the last twelve months (peer median +2.5%); the operating margin is 10.9% (peer median 0.9%).
Valuation It trades at 1.7× enterprise value to sales against a peer median of 1.2× (7th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.6 points above its cost of capital (5.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.38B | HK$1.39B | HK$1.66B | HK$1.73B | HK$1.81B |
| Revenue growth | — | -16% | -4% | -4% | — |
| Gross profit | HK$717M | HK$680M | HK$741M | HK$738M | HK$908M |
| EBITDA | HK$182M | HK$189M | HK$236M | HK$169M | HK$286M |
| Net income | HK$137M | HK$124M | HK$164M | HK$153M | HK$274M |
| Free cash flow | HK$243M | HK$210M | HK$178M | -HK$174M | HK$36.4M |
| Capital expenditure | HK$19.0M | HK$32.6M | HK$59.8M | HK$49.2M | HK$86.4M |
| Total debt | n/a | HK$157M | HK$80.1M | HK$81.5M | HK$42.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1345.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.3% | -0.8% | 6th lowest of 21 |
| 6-month return | -17.7% | -5.6% | 7th lowest of 21 |
| Distance from 52-week high | -18.8% | -27.2% | 9th highest of 21 |
| Revenue growth (TTM) | -5.8% | +2.5% | 5th lowest of 21 |
| Operating margin | 10.9% | 0.9% | 3rd highest of 21 |
| EV / Sales | 1.7× | 1.2× | 7th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -6.7% | 4.0% | 3rd least demanding of 15 |
| Growth delivered (Del g) | -1.4% | +5.8% | 3rd lowest of 15 |
| Hurdle (Req g minus delivered) | -5.2 pp | -2.9 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +5.6 pp | -2.4 pp | highest of 20 |
| EV / EBITDA | 12.7× | 7.2× | 2nd most expensive of 4 |
| Net debt / EBITDA | -0.2× | 1.3× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Pioneer 1345.HK | Hong Kong | $300M | -18% | -6% | 11% | 1.7× | -6.7% | -1.4% |
| Nagaileben 7447.T | Japan | $319M | -1% | +1% | 22% | 1.6× | n/a | n/a |
| Goodwill E-Health Info 688246.SS | China | $323M | -25% | -30% | -68% | 6.4× | n/a | n/a |
| Medios ILM1.DE | Germany | $324M | -9% | +10% | 2% | 0.2× | -1.3% | +27.1% |
| Rongfeng 000668.SZ | China | $327M | -5% | +61% | 14% | 5.3× | 11.4% | +30.0% |
| Shanghai Universal Biotech 301166.SZ | China | $376M | -6% | +15% | -4% | 1.2× | n/a | n/a |
| Gongwin Biopharm 6617.TWO | Taiwan | $388M | +50% | +22% | -571% | 267.5× | n/a | n/a |
| Excelsior Medical 4104.TW | Taiwan | $409M | +1% | +6% | 8% | 1.6× | 2.9% | +5.7% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | 0.1× | 0.4% | +2.6% |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | 0.6× | 59.0% | -7.8% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | 4.1× | n/a | n/a |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | 1.2× | 12.2% | -18.1% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 0.1× | -7.1% | +3.8% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | 0.8× | 14.4% | +7.5% |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | 2.4× | 0.3% | +1.0% |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $926M | -27% | -5% | -2% | 2.0× | 17.2% | +12.4% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |